Published in Fam Cancer on January 01, 2008
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer (2009) 18.53
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28
Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer (2010) 1.15
Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am (2008) 1.00
A systematic review of the indications for genetic testing and prophylactic gastrectomy among patients with hereditary diffuse gastric cancer. Gastric Cancer (2011) 0.99
Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med (2014) 0.94
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One (2015) 0.89
The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC. Eur J Hum Genet (2012) 0.87
Plasmacytoid urothelial carcinoma of the bladder metastatic to the stomach: a case report. Case Rep Urol (2012) 0.86
Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer. Virchows Arch (2013) 0.84
Hereditary breast cancer in the Han Chinese population. J Epidemiol (2013) 0.83
CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Fam Cancer (2010) 0.83
Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer. Mol Genet Genomic Med (2016) 0.81
Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature. BMC Gastroenterol (2013) 0.80
Family history of malignant neoplasm and its relation with clinicopathologic features of gastric cancer patients. World J Surg Oncol (2013) 0.78
Emerging Concepts in Breast Cancer Risk Prediction. Curr Obstet Gynecol Rep (2013) 0.78
Prophylactic Laparoscopic Total Gastrectomy with Jejunal Pouch Reconstruction in Patients Carrying a CDH1 Germline Mutation. J Gastrointest Surg (2015) 0.77
Putative linkage signals identified for breast cancer in African American families. Cancer Epidemiol Biomarkers Prev (2014) 0.75
The identification and management of hereditary diffuse gastric cancer in a large Jordanian family. Fam Cancer (2011) 0.75
[Genes beyond BRCA1 and BRCA2 for hereditary breast cancer]. Wien Med Wochenschr (2010) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Epidemiology of gastric cancer. World J Gastroenterol (2006) 7.67
E-cadherin germline mutations in familial gastric cancer. Nature (1998) 6.72
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med (1989) 6.24
Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology (2000) 5.40
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55
E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res (1994) 4.51
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97
Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem (1996) 3.95
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res (2004) 3.90
Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol (2000) 3.88
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci (1999) 3.55
E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene (1996) 3.35
Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med (2001) 3.27
Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst (2005) 3.09
Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology (2001) 3.00
Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet (2004) 2.95
Mutations of the human E-cadherin (CDH1) gene. Hum Mutat (1998) 2.84
Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol (1993) 2.84
The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet (1986) 2.78
Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch Pathol Lab Med (2004) 2.73
Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci (2007) 2.41
Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene (2001) 2.36
Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet (2000) 2.29
E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg (2000) 2.18
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet (2000) 2.15
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res (2001) 2.14
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg (2007) 2.10
Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci (1999) 1.83
Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet (2001) 1.77
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res (2005) 1.70
ATM and breast cancer susceptibility. Oncogene (2006) 1.68
Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer (2001) 1.64
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res (2004) 1.62
Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol (1999) 1.61
Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol (2004) 1.59
Gastric cancer: new genetic developments. J Surg Oncol (2005) 1.55
E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene (2001) 1.54
Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer (1996) 1.48
E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest (1999) 1.47
Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res (2005) 1.46
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer (2007) 1.45
Role of p120-catenin in cadherin trafficking. Biochim Biophys Acta (2006) 1.44
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat (2002) 1.44
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet (2004) 1.38
Cowden's disease: a cutaneous marker of breast cancer. Cancer (1978) 1.36
Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet (2007) 1.28
Lobular breast cancer: excess familiality observed in the Utah Population Database. Int J Cancer (2005) 1.20
E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer (2004) 1.17
The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol (2003) 1.17
CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. Int J Cancer (2002) 1.13
Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut (2005) 1.09
Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis (2006) 1.07
Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer (2000) 1.07
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer (2005) 1.05
Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. Am J Hum Genet (1989) 1.05
Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res (2001) 1.04
Breast cancer in an MSH2 gene mutation carrier. Hum Pathol (2005) 1.03
Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease. Surgery (1995) 1.02
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat (2002) 0.97
Ataxia-telangiectasia with gastric adenocarcinoma. JAMA (1969) 0.94
BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer (2002) 0.94
Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst (1995) 0.93
Recognition and management of hereditary breast cancer syndromes. Oncologist (2004) 0.92
Stomach cancer of a 14-year-old boy with ataxia-telangiectasia. Tohoku J Exp Med (1977) 0.91
A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet (2004) 0.89
[18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res (2004) 0.88
Loss of hMSH2 expression in primary breast cancer with p53 alterations. Oncol Rep (2004) 0.87
New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol (2007) 0.86
Early gastric cancer development in a familial adenomatous polyposis patient. Dig Dis Sci (2004) 0.83
Werner's syndrome combined with quintuplicate malignant tumors: a case report and review of literature data. Jpn J Clin Oncol (1991) 0.81
Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res (2000) 0.79
Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast. Postgrad Med J (1994) 0.79
The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann N Y Acad Sci (2001) 0.79
Gastric adenocarcinoma in a patient with xeroderma pigmentosum. Br J Dermatol (1985) 0.77
International network of cancer genome projects. Nature (2010) 20.35
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin (2007) 12.19
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Colorectal cancer. Lancet (2010) 8.36
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet (2010) 6.74
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA (2008) 5.25
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol (2011) 4.66
Offering individual genetic research results: context matters. Sci Transl Med (2010) 4.51
American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin (2003) 4.43
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet (2013) 4.06
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Reconsidering the family history in primary care. J Gen Intern Med (2004) 3.50
Genomic research and wide data sharing: views of prospective participants. Genet Med (2010) 3.45
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet Med (2012) 3.29
Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics (2010) 3.29
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. JAMA (2006) 3.20
ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol (2007) 3.19
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer (2007) 3.09
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer (2008) 2.95
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60
Newborn screening technology: proceed with caution. Pediatrics (2006) 2.54
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res (2004) 2.51
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol (2007) 2.48
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol (2007) 2.47
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis (2002) 2.41
Science and regulation. Regulating direct-to-consumer personal genome testing. Science (2010) 2.40
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
The genomic applications in practice and prevention network. Genet Med (2009) 2.39
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
FOXA1 expression in breast cancer--correlation with luminal subtype A and survival. Clin Cancer Res (2007) 2.22
Pharmacogenetic testing: not as simple as it seems. Genet Med (2008) 2.18
Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nat Genet (2003) 2.11
CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg (2007) 2.10
The FDA and genomic tests--getting regulation right. N Engl J Med (2015) 2.09